Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV003107367 | SCV003793544 | pathogenic | Smith-Lemli-Opitz syndrome | 2022-01-03 | criteria provided, single submitter | clinical testing | This variant results in the deletion of exon 6 and part of exon 5 (c.403_626+24del) of the DHCR7 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in DHCR7 are known to be pathogenic (PMID: 9634533, 10677299). This variant has not been reported in the literature in individuals affected with DHCR7-related conditions. This variant disrupts a region of the DHCR7 protein in which other variant(s) (p.Thr154Met) have been determined to be pathogenic (PMID: 10677299, 10995508, 11427181, 15896653, 18249054, 22391996). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |